PDSB

Company Overview — What Does PDS Biotechnology Corp Do?

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey. PDS Biotechnology Corp (PDSB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Frank K. Bedu-Addo and employs approximately 20 people, headquartered in Princeton, New Jersey. With a market capitalization of $33M, PDSB is one of the notable companies in the Healthcare sector.

PDS Biotechnology Corp (PDSB) Stock Rating — Avoid (April 2026)

As of April 2026, PDS Biotechnology Corp receives a Avoid rating with a composite score of 20.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.PDSB ranks #4,382 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, PDS Biotechnology Corp ranks #816 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PDSB Stock Price and 52-Week Range

PDS Biotechnology Corp (PDSB) currently trades at $1.09. The stock gained $0.02 (1.9%) in the most recent trading session. The 52-week high for PDSB is $1.92, which means the stock is currently trading -43.1% from its annual peak. The 52-week low is $0.60, putting the stock 81.3% above its annual trough. Recent trading volume was 997K shares, suggesting relatively thin trading activity.

Is PDSB Overvalued or Undervalued? — Valuation Analysis

PDS Biotechnology Corp (PDSB) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.42x, versus the sector average of 2.75x.

At current multiples, PDS Biotechnology Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

PDS Biotechnology Corp Profitability — ROE, Margins, and Quality Score

PDS Biotechnology Corp (PDSB) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -398.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -108.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PDSB Debt, Balance Sheet, and Financial Health

PDS Biotechnology Corp has a debt-to-equity ratio of 190.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. Total debt on the balance sheet is $18M. Cash and equivalents stand at $26M.

PDSB has a beta of 1.63, meaning it is more volatile than the broader market — a $10,000 investment in PDSB would be expected to move 63.2% more than the S&P 500 on any given day. The stability factor score for PDS Biotechnology Corp is 23/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

PDS Biotechnology Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, PDS Biotechnology Corp reported revenue of $0 and earnings per share (EPS) of $-0.19. Net income for the quarter was $-38M. Operating income came in at $-35M.

In Q3 2025, PDS Biotechnology Corp reported revenue of $0 and earnings per share (EPS) of $-0.19. Net income for the quarter was $-9M. Operating income came in at $-8M.

In Q2 2025, PDS Biotechnology Corp reported revenue of $0 and earnings per share (EPS) of $-0.21. Net income for the quarter was $-9M. Operating income came in at $-8M.

In Q1 2025, PDS Biotechnology Corp reported revenue of $0 and earnings per share (EPS) of $-0.21. Net income for the quarter was $-8M. Operating income came in at $-9M.

Over the past 8 quarters, PDS Biotechnology Corp has experienced revenue contraction from $0 to $0. Investors analyzing PDSB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PDSB Dividend Yield and Income Analysis

PDS Biotechnology Corp (PDSB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PDSB Momentum and Technical Analysis Profile

PDS Biotechnology Corp (PDSB) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

PDSB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, PDS Biotechnology Corp (PDSB) ranks #816 out of 838 stocks based on the Blank Capital composite score. This places PDSB in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PDSB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PDSB vs S&P 500 (SPY) comparison to assess how PDS Biotechnology Corp stacks up against the broader market across all factor dimensions.

PDSB Next Earnings Date

No upcoming earnings date has been announced for PDS Biotechnology Corp (PDSB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PDSB? — Investment Thesis Summary

The quantitative profile for PDS Biotechnology Corp suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 23/100) increases portfolio risk.

In summary, PDS Biotechnology Corp (PDSB) earns a Avoid rating with a composite score of 20.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PDSB stock.

Related Resources for PDSB Investors

Explore more research and tools: PDSB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PDSB head-to-head with peers: PDSB vs AZN, PDSB vs SLGL, PDSB vs VMD.